Bristol settles inventory class action
Bristol-Myers Squibb has $170 mil. left in its legal reserve for wholesaler inventory litigation after paying $300 mil. to settle a securities class action lawsuit. The settlement is related to inventory accounting and Bristol's investment in ImClone's Erbitux. Bristol increased its legal reserves for wholesaler inventory litigation by $320 mil. to $470 mil. in the second quarter. The $320 mil. reserve was the majority of a $455 mil. second quarter charge for litigation-related expenses. Bristol expected the charge would total $400 mil. (1"The Pink Sheet" July 5, 2004, p. 28)...
You may also be interested in...
Bristol-Myers Squibb plans to increase its legal reserves relating to wholesaler inventory issues by $300 mil., the second increase in three months
In this edition of the Device Week podcast, Medtech Insight managing editor Marion Webb discusses LifeSignals’ plans for a vital-sign monitoring patch that could help remotely monitor patients during the pandemic. Deputy editor Reed Miller highlights some important device trials presented at the American College of Cardiology online conference.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.